Phoenix Asia vs PMA Graphene Technology
PHOE and PMA side by side, both in construction special trade contractors. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PHOE and PMA compare
Phoenix Asia grew revenue faster over the last twelve months (−2.2% versus −56.8% for PMA Graphene Technology).
Phoenix Asia keeps more of each dollar of sales as profit, with a net margin of −16.7% compared with −39.4% at PMA Graphene Technology.
Phoenix Asia scores higher on the StockData Score (5 against 0 for PMA Graphene Technology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PHOE | PMA |
|---|---|---|
| Size and price | ||
| Share price | $15.79 | $1.36 |
| Change, 1 year | −5.3% | −27.7% |
| Beta (5Y) | 0.09 | 1.09 |
| Employees | 32 | 7 |
| StockData Score | ||
| Total score | 5 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −2.2% (better) | −56.8% |
| Net income growth (TTM) | −217% | – |
| EPS growth (TTM) | −200% | – |
| Profitability | ||
| Gross margin | 4.6% (better) | −18.4% |
| Operating margin | −16.8% (better) | −37.4% |
| Net margin | −16.7% (better) | −39.4% |
| Return on equity | −25.9% | – |
| Return on invested capital | −31.9% (better) | −53.4% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −487.7× | −15.8× (better) |
| Current ratio | 5.46 (better) | 0.71 |
| Piotroski F-score | 2 | 2 |
| Ownership | ||
| Held by institutions | – | 0.77% |
| Held by insiders | 74.5% | 68.1% |
| Insider net buying, 12 months | – | −$1.7M |
| Short interest, % of float | 0.02% | 2.5% |
Go deeper
- PHOE stock overview
- PHOE income statement
- PHOE valuation and score
- PMA stock overview
- PMA income statement
- PMA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.